28 Thyroid Cancer 1 1 0 4 4 894 http://clinicaltrials.dfhcc.harvard.edu/trials/894 Efficacy Study of XL184 in Adults With Medullary Thyroid Cancer The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration. The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD. Site/location information will be updated periodically. Recruiting 28 Thyroid Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/28-thyroid-cancer Phase 3 1142 http://clinicaltrials.dfhcc.harvard.edu/trials/1142 Preoperative Treatment of Patients With High Risk Thymoma This is a phase II study for patients with thymoma or thymic carcinoma thought to be at significant risk for recurrence following surgical removal. This study involves the use of combined chemotherapy and radiation therapy prior to surgery, in hopes of increasing the chances of complete resection. The chemoradiotherapy protocol is one which has been used extensively for other diseases, and the side effects are therefore well-documented. Patients with thymomas thought to be at significant risk for recurrence (by x-ray and pathology criteria) will be allowed to participate, and will undergo combined chemotherapy with radiation to the chest followed by surgical removal of the tumor and postoperative chemotherapy. The main outcome measured will be the rate of pathological complete response (e.g. no active tumor in the resected specimen) to the preoperative treatment. Patients will receive postoperative treatment based on surgical and pathologic criteria. Recruiting 28 Thyroid Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/28-thyroid-cancer Phase 2 1161 http://clinicaltrials.dfhcc.harvard.edu/trials/1161 RAD001 for Patients With Radioiodine Refractory Thyroid Cancer Since thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an inhibitor of the mTOR pathway and has shown activity in neuroendocrine cancers of the gastrointestinal tract and has been approved for the treatment of metastatic renal cell cancer. Recruiting 28 Thyroid Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/28-thyroid-cancer Phase 2 993 http://clinicaltrials.dfhcc.harvard.edu/trials/993 A Phase 1/2 Dose Finding Study of an Experimental New Drug CS7017, an Oral PPARγ Agonist Taken by Mouth Twice Daily in Combination With Paclitaxel Chemotherapy The Phase I/II study will be conducted as an open label, multiple center study of CS-7017, an experimental drug and paclitaxel chemotherapy in subjects with advanced anaplastic thyroid cancer. Biopsies will be obtained from patients with accessible tumor at baseline, two-weeks after the first CS-7017 dosage (prior to the start of combination therapy) and at the end of the first study cycle (week 3 of combination therapy), in order to evaluate the effects of the study drug alone and in combination with the chemotherapy agent on the tumor. Treatment will continue until disease progression or the development of intolerable toxicities. Recruiting 28 Thyroid Cancer http://clinicaltrials.dfhcc.harvard.edu/diagnoses/28-thyroid-cancer Phase 1/Phase 2